Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

Literature DB >> 21191675

Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

Deborah A Thomas¹, Susan O'Brien, Stefan Faderl, John T Manning, Jorge Romaguera, Luis Fayad, Fredrick Hagemeister, Jeffrey Medeiros, Jorge Cortes, Hagop Kantarjian.

Abstract

Burkitt lymphoma (BL) is a mature B-cell non-Hodgkin lymphoma with an aggressive clinical course. Since the advent of short, intensive, multiagent chemoimmunotherapy regimens, it has carried a favorable prognosis. BL has been rather well characterized, whereas the other lymphomas morphologically resembling it are more heterogeneous. The cases classified as atypical BL/Burkitt-like lymphoma by the 2001 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissue were thought to represent a continuum between BL and diffuse large B-cell lymphoma (DLBCL). The optimal therapeutic strategy for this provisional entity was not definitively established. However, recent incorporation of molecular genetic data into the 2008 WHO Classification has allowed further refinements with significant therapeutic implications, including the designation of a new provisional entity, "B-cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL." This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Antineoplastic Agents

Year: 2011 PMID： 21191675 PMCID： PMC4394740 DOI： 10.1007/s11899-010-0076-4

Source DB: PubMed Journal: Curr Hematol Malig Rep ISSN： 1558-8211 Impact factor: 3.952

38 in total

1. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Authors: Matija Snuderl; Olga K Kolman; Yi-Bin Chen; Jessie J Hsu; Adam M Ackerman; Paola Dal Cin; Judith A Ferry; Nancy Lee Harris; Robert P Hasserjian; Lawrence R Zukerberg; Jeremy S Abramson; Ephraim P Hochberg; Hang Lee; Alfred I Lee; Christiana E Toomey; Aliyah R Sohani
Journal: Am J Surg Pathol Date: 2010-03 Impact factor: 6.394

2. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

Authors: Gustaaf W van Imhoff; Evert-Jan G Boerma; Bronno van der Holt; Ed Schuuring; Leo F Verdonck; Hanneke C Kluin-Nelemans; Philip M Kluin
Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544

3. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.

Authors: Rebecca F McClure; Ellen D Remstein; William R Macon; Gordon W Dewald; Thomas M Habermann; Antje Hoering; Paul J Kurtin
Journal: Am J Surg Pathol Date: 2005-12 Impact factor: 6.394

Review 4. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology.

Authors: Antonino Carbone; Annunziata Gloghini; Antonella Aiello; Adele Testi; Antonello Cabras
Journal: Hum Pathol Date: 2010-05 Impact factor: 3.466

5. Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features.

Authors: T Burmeister; S Schwartz; H-A Horst; H Rieder; N Gökbuget; D Hoelzer; E Thiel
Journal: Leukemia Date: 2005-08 Impact factor: 11.528

Review 6. Spectrum of Epstein-Barr virus-associated diseases.

Authors: J L Kutok; F Wang
Journal: Annu Rev Pathol Date: 2006 Impact factor: 23.472

7. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

Authors: Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack
Journal: Blood Date: 2008-07-08 Impact factor: 22.113

8. Improved outcome in adult B-cell acute lymphoblastic leukemia.

Authors: D Hoelzer; W D Ludwig; E Thiel; W Gassmann; H Löffler; C Fonatsch; H Rieder; G Heil; B Heinze; R Arnold; D Hossfeld; T Büchner; P Koch; M Freund; W Hiddemann; G Maschmeyer; A Heyll; C Aul; T Faak; R Kuse; T H Ittel; M Gramatzki; H Diedrich; K Kolbe; H G Fuhr; K Fischer; C Schadeck-Gressel; A Weiss; I Strohscheer; B Metzner; U Fabry; N Gökbuget; B Völkers; D Messerer; K Uberla
Journal: Blood Date: 1996-01-15 Impact factor: 22.113

9. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.

Authors: G M Mead; M R Sydes; J Walewski; A Grigg; C S Hatton; N Pescosta; C Guarnaccia; M S Lewis; J McKendrick; S P Stenning; D Wright; P Norbert
Journal: Ann Oncol Date: 2002-08 Impact factor: 32.976

Review 10. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors: N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal: Blood Date: 1994-09-01 Impact factor: 22.113

10 in total

1. Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.

Authors: L Smyth; P V Browne; E Conneally; C Flynn; P Hayden; M Jeffers; D O'Brien; F Quinn; J Kelly; M Perera; G M Crotty; M Leahy; B Hennessy; F Jackson; M Ryan; E Vandenberghe
Journal: Ir J Med Sci Date: 2015-04-07 Impact factor: 1.568

2. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.

Authors: Nicholas J Short; Hagop M Kantarjian; Heidi Ko; Joseph D Khoury; Farhad Ravandi; Deborah A Thomas; Guillermo Garcia-Manero; Maria Khouri; Jorge E Cortes; William G Wierda; Srdan Verstovsek; Zeev Estrov; Alessandra Ferrajoli; Philip A Thompson; Sherry Pierce; Susan M O'Brien; Elias Jabbour
Journal: Am J Hematol Date: 2017-04-18 Impact factor: 10.047

Review 3. The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.

Authors: Pei Lin; L Jeffrey Medeiros
Journal: Curr Hematol Malig Rep Date: 2013-09 Impact factor: 3.952

4. Diagnostic Dilemma in the Morphological Detection of Flower Cells in Lymphomas.

Authors: Neha Singh; Jatin Gandhi; Narendra Agrawal; Ajit Panaych; Narender Tejwani; Anurag Mehta
Journal: Indian J Hematol Blood Transfus Date: 2017-01-27 Impact factor: 0.900

5. Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.

Authors: James R Cook; Bryan Goldman; Raymond R Tubbs; Lisa Rimsza; Michael Leblanc; Patrick Stiff; Richard Fisher
Journal: Am J Surg Pathol Date: 2014-04 Impact factor: 6.394

6. Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas.

Authors: Chulin Sha; Sharon Barrans; Matthew A Care; David Cunningham; Reuben M Tooze; Andrew Jack; David R Westhead
Journal: Genome Med Date: 2015-07-01 Impact factor: 11.117

7. Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.

Authors: Junshik Hong; Seok Jin Kim; Jae-Sook Ahn; Moo Kon Song; Yu Ri Kim; Ho Sup Lee; Ho-Young Yhim; Dok Hyun Yoon; Min Kyoung Kim; Sung Yong Oh; Yong Park; Yeung-Chul Mun; Young Rok Do; Hun-Mo Ryoo; Je-Jung Lee; Jae Hoon Lee; Won Seog Kim; Cheolwon Suh
Journal: Cancer Res Treat Date: 2014-10-28 Impact factor: 4.679